California-based Crescendo Bioscience, a molecular diagnostics company that develops and commercializes quantitative, biology-based tests for rheumatoid arthritis (RA) and other autoimmune diseases, has received accreditation from the Commission on Laboratory Accreditation of the College of American Pathologists (CAP) based on the results of an on-site laboratory inspection. This follows the recent laboratory permit issued by the New York Department of Health Clinical Laboratory Evaluation Program (CLEP) to Crescendo Bioscience.
In announcing the accreditation, William A. Hagstrom, President and CEO of Crescendo Bioscience, says that his company “has developed a highly accurate and precise multi-biomarker blood test, Vectra DA, which measures disease activity in RA by integrating 12 key proteins consistently associated with RA’s biology into one single, objective and quantitative score.” Vectra DA testing is performed at Crescendo Bioscience’s CLIA (Clinical Laboratory Improvement Amendments) facility and test results are reported back within seven to 10 days of receipt of sample. Physicians can receive test results either via standard mail or fax or via the private web portal, VectraView. Learn more about Vectra DA, and view an informative video, “Measuring Rheumatoid Arthritis at the Molecular Level.”
